Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lupin gets USFDA nod...

    Lupin gets USFDA nod to Methylprednisolone tablets to treat inflammation

    Farhat NasimWritten by Farhat Nasim Published On 2019-02-26T09:50:26+05:30  |  Updated On 16 Aug 2021 4:44 PM IST

    The company has received approval from the US Food and Drug Administration (USFDA) to market Methylprednisolone tablets, a generic version of Pharmacia and Upjohn Company's Medrol tablets, Lupin said in a statement.


    Mumbai: Mumbai-based drugmaker, Lupin recently said it has received approval from the US health regulator to market Methylprednisolone tablets used for treatment of inflammation in many conditions.




    Methylprednisolone works by decreasing inflammation and changing your body's immune response. Methylprednisolone is used to reduce inflammation in many conditions. These include endocrine diseases, severe allergies, ulcerative colitis, and multiple sclerosis. It's also used to treat rheumatic diseases, such as rheumatoid arthritis and osteoarthritis.


    The company has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Pharmacia and Upjohn Company's Medrol tablets, Lupin said in a statement.


    Also Read: Lupin gets USFDA tentative approval for generic tablets to treat Erectile Dysfunction


    The drug is indicated to treat endocrine and rheumatic disorders, among others.


    As per IQVIA MAT December 2018 data, the company said, Methylprednisolone tablets had annual sales of around $ 114.3 million in the US.


    Lupin was founded in 1968 by Desh Bandhu Gupta, then an Associate Professor at BITS-Pilani, Rajasthan. Gupta died on 26 June 2017 and was replaced as chairman by his wife, Manju Deshbandhu Gupta.


    The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.


    Also Read: Relief to Lupin: High court removes ban its diabetes drug Gluconorm P 30

    FDAindian pharma newsinflammation drugLupinmedrolMedrol tabletsmethylprednisoloneMethylprednisolone tabletsMumbaipharma newsPharmaciaUpjohn CompanyUSUSFDAUSFDA approval
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok